Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025
Tourmaline Bio (NASDAQ: TRML), a late-stage clinical biotechnology company focused on developing transformative medicines for immune and inflammatory diseases, has announced its participation in the upcoming Leerink's Global Healthcare Conference 2025.
The company's Co-Founder and CEO, Sandeep Kulkarni, MD, will engage in a fireside chat scheduled for Tuesday, March 11, 2025, at 4:20 pm ET in Miami. Interested parties can access both the live webcast and replay through the 'Events and Presentations' section under News & Investors on Tourmaline Bio's website at ir.tourmalinebio.com.
Tourmaline Bio (NASDAQ: TRML), una società biotecnologica clinica in fase avanzata focalizzata sullo sviluppo di farmaci trasformativi per malattie immunitarie e infiammatorie, ha annunciato la sua partecipazione alla prossima Conferenza Globale sulla Salute di Leerink 2025.
Il co-fondatore e CEO dell'azienda, Sandeep Kulkarni, MD, parteciperà a una chiacchierata informale programmata per martedì 11 marzo 2025, alle 16:20 ET a Miami. Le parti interessate possono accedere sia alla diretta che alla registrazione attraverso la sezione 'Eventi e Presentazioni' sotto Notizie e Investitori sul sito web di Tourmaline Bio all'indirizzo ir.tourmalinebio.com.
Tourmaline Bio (NASDAQ: TRML), una compañía biotecnológica clínica en etapa avanzada enfocada en desarrollar medicamentos transformadores para enfermedades inmunitarias e inflamatorias, ha anunciado su participación en la próxima Conferencia Global de Salud de Leerink 2025.
El cofundador y CEO de la compañía, Sandeep Kulkarni, MD, participará en una charla informal programada para martes 11 de marzo de 2025, a las 4:20 pm ET en Miami. Las partes interesadas pueden acceder tanto a la transmisión en vivo como a la repetición a través de la sección 'Eventos y Presentaciones' en Noticias e Inversores en el sitio web de Tourmaline Bio en ir.tourmalinebio.com.
투르말린 바이오 (NASDAQ: TRML)는 면역 및 염증 질환을 위한 혁신적인 의약품 개발에 집중하는 후기 단계 임상 생명공학 회사로, 다가오는 리어링크 글로벌 헬스케어 컨퍼런스 2025에 참여한다고 발표했습니다.
회사의 공동 창립자이자 CEO인 산딥 쿨카르니 박사(MD)는 2025년 3월 11일 화요일 오후 4시 20분 ET에 마이애미에서 예정된 대담에 참여할 예정입니다. 관심 있는 분들은 투르말린 바이오 웹사이트의 뉴스 및 투자자 섹션에 있는 '이벤트 및 프레젠테이션'을 통해 생중계와 재생을 모두 이용할 수 있습니다: ir.tourmalinebio.com.
Tourmaline Bio (NASDAQ: TRML), une société de biotechnologie clinique en phase avancée axée sur le développement de médicaments transformateurs pour les maladies immunitaires et inflammatoires, a annoncé sa participation à la prochaine Conférence Mondiale sur la Santé de Leerink 2025.
Le co-fondateur et PDG de l'entreprise, Sandeep Kulkarni, MD, participera à une discussion informelle prévue pour mardi 11 mars 2025, à 16h20 ET à Miami. Les parties intéressées peuvent accéder à la fois à la diffusion en direct et à la rediffusion via la section 'Événements et Présentations' sous Actualités et Investisseurs sur le site web de Tourmaline Bio à l'adresse ir.tourmalinebio.com.
Tourmaline Bio (NASDAQ: TRML), ein Unternehmen der klinischen Biotechnologie in der späten Phase, das sich auf die Entwicklung transformierender Medikamente für immunologische und entzündliche Erkrankungen konzentriert, hat seine Teilnahme an der bevorstehenden Leerink Global Healthcare Conference 2025 angekündigt.
Der Mitbegründer und CEO des Unternehmens, Sandeep Kulkarni, MD, wird an einem informellen Gespräch teilnehmen, das für Dienstag, den 11. März 2025, um 16:20 Uhr ET in Miami angesetzt ist. Interessierte Parteien können sowohl auf den Live-Stream als auch auf die Wiederholung über den Bereich 'Veranstaltungen und Präsentationen' unter Nachrichten & Investoren auf der Website von Tourmaline Bio unter ir.tourmalinebio.com zugreifen.
- None.
- None.
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conference:
Leerink's Global Healthcare Conference 2025, Miami
Fireside Chat
Tuesday, March 11, 2025, at 4:20 pm ET
A live webcast and replay, when available, will be available under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at ir.tourmalinebio.com.
About Tourmaline Bio
Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006). For more information about Tourmaline Bio and pacibekitug, please visit https://www.tourmalinebio.com or follow us on LinkedIn or X.
Media Contact
Scient PR
Sarah Mishek
SMishek@ScientPR.com
Investor Contact
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com
FAQ
When is Tourmaline Bio (TRML) presenting at the Leerink Global Healthcare Conference 2025?
How can investors watch Tourmaline Bio's (TRML) presentation at the Leerink Conference?
What type of diseases does Tourmaline Bio (TRML) focus on treating?
Who will represent Tourmaline Bio (TRML) at the Leerink Healthcare Conference 2025?
